Biora Therapeutics Inc (BIOR) News

Form S-3 - Registration statement under Securities Act of 1933

Form S-3 - Registration statement under Securities Act of 1933

Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024

SAN DIEGO, May 20, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that...

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in...

Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that...

Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that...

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

Dosing of all patients in the trial has been successfully completed Final results are expected to be available...

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company...

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in...

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company...

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company...

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results...

U.S. Index Futures on the Rise, Oil Prices Show Stability

U.S. index futures are showing an uptrend in pre-market trading this Tuesday, with investors keen on driving a...

Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company...

Form 8-K - Current report